Searched for: in-biosketch:true
person:murrak09
MULTIPLE PRIMARY MALIGNANCIES IN RENAL CORTICAL NEOPLASMS: AN UPDATED EVALUATION [Meeting Abstract]
Murray, Katie S.; Zabor, Emily C.; Spaliviero, Massimiliano; Russo, Paul; Bazzi, Wassim M.; Musser, John E.; Hakimi, A. Ari; Bernstein, Melanie L.; Dalbagni, Guido; Coleman, Jonathan A.; Furberg, Helena
ISI:000362826500154
ISSN: 0022-5347
CID: 5355622
TREATMENT OF THE PRIMARY TUMOR WITH VASCULAR-TARGETED PHOTODYNAMIC THERAPY (VTP) OVERCOMES RESISTANCE TO SYSTEMIC PD-1/PD-L1 INHIBITION: EFFECTS ON PRIMARY TUMOR CONTROL AND PREVENTION OF LUNG METASTASIS IN A PRE-CLINICAL RCC MODEL [Meeting Abstract]
O\Shaughnessy, Matthew; Murray, Katie; LaRosa, Stephen; Monette, Sebastien; Kim, Kwanghee; Beluco, Renato; Fonseca, Corradi; Scherz, Avigdor; Coleman, Jonathan
ISI:000362826500376
ISSN: 0022-5347
CID: 5355632
PHASE 3 RANDOMIZED TRIAL OF INTRAVENOUS MANNITOL VERSUS PLACEBO PRIOR TO RENAL ISCHEMIA DURING PARTIAL NEPHRECTOMY: IMPACT ON RENAL FUNCTIONAL OUTCOMES [Meeting Abstract]
Spaliviero, Massimiliano; Power, Nicholas E.; Murray, Katie S.; Russo, Paul; Sjoberg, Daniel D.; Benfante, Nicole E.; Sun, Arony J.; Bernstein, Melanie L.; Touijer, Karim A.; Dalbagni, Guido; Coleman, Jonathan A.
ISI:000362826500570
ISSN: 0022-5347
CID: 5355642
IRREVERSIBLE ELECTROPORATION (IRE) AS A LOCALIZED TREATMENT FOR PROSTATE CANCER: A REPORT ON SAFETY AND OUTCOMES [Meeting Abstract]
Murray, Katie; Musser, John; Mashni, Joseph; Srimathveeravalli, Govindarajan; Durack, Jeremy; Solomon, Stephen; Coleman, Jonathan
ISI:000362826600293
ISSN: 0022-5347
CID: 5355652
Urologic considerations
Chapter by: Murray, Katie S; Griebling, TL
in: The 5-minute urology consult by Gomella, Leonard G [Ed]
Philadelphia : Wolters Kluwer, [2015]
pp. 480-481
ISBN: 9781451189988
CID: 5444722
Andropause (Late-Onset hypogonadism)
Chapter by: Murray, Katie S; Griebling, TL
in: The 5-minute urology consult by Gomella, Leonard G [Ed]
Philadelphia : Wolters Kluwer, [2015]
pp. 28-29
ISBN: 9781451189988
CID: 5444732
Enuresis adult
Chapter by: Murray, Katie S; Griebling, TL
in: The 5-minute urology consult by Gomella, Leonard G [Ed]
Philadelphia : Wolters Kluwer, [2015]
pp. 132-133
ISBN: 9781451189988
CID: 5444742
Modifier 22 Reimbursement for Patients Undergoing Robot-Assisted Laparoscopic Prostatectomy at a Tertiary Referral Center
Murray, Katie S; Mirza, Moben; Zainfeld, Daniel; Corono, Ernesto-Lopez; Thrasher, J Brantley; Duchene, David A
ORIGINAL:0016632
ISSN: 2352-0779
CID: 5444662
Modifier 22 on perioperative outcomes of robotic assisted laparoscopic prostatectomy
Murray, Katie S; Griffin, Joshua; Feng, Yuan; Mirza, Moben; Thrasher, J Brantley; Lopez-Corona, Ernesto; Duchene, David A
INTRODUCTION/BACKGROUND:Robotic assisted laparoscopic prostatectomy (RALP) is a mainstay in the treatment of prostate cancer. Current procedure terminology (CPT) identifies a case that requires substantially greater effort than usual by using the modifier 22 code (M22). Our objective was to identify the most common etiologies leading to M22 at our institution and determine the effect on perioperative outcomes. MATERIALS AND METHODS/METHODS:We retrospectively reviewed our prostatectomy database from 2009-2012 to identify patients who underwent RALP with and without M22. Reasons for M22 were determined by review of operative reports. Comparisons were made using Chi-square analysis and independent t-tests for continuous data. RESULTS:Of 579 patients identified from our database, 208 (36%) had a M22. Eighty-six (41%) patients had ≥ 2 documented reasons for M22. Adhesiolysis was the most common reason for M22 followed by large prostate and previous hernia mesh. Body mass index (BMI) (29.8 versus 28), prostate volume (53 g versus 44 g), operative time (259 minutes versus 234 minutes), and discharge from hospital with pelvic drain in place (6.7% versus 3%) were all significantly higher in the M22 group. Final pathological stage and positive margin rate were not increased in those with a M22. Complications were not different between those with and without M22. CONCLUSION/CONCLUSIONS:The M22 code is associated with longer operative times, larger prostates, and higher BMI. Adverse effects on final pathological stage, margin status and complications were not found in those with M22. Many patients with a M22 have more than one reason documented as for the explanation of the modifier.
PMID: 25171284
ISSN: 1195-9479
CID: 5355032
A PROSPECTIVE STUDY OF ERECTILE FUNCTION AND URINARY SYMPTOMS AFTER TRANSRECTAL ULTRASOUND AND PROSTATE BIOPSY IN MEN [Meeting Abstract]
Murray, Katie; Lopez-Corona, Ernesto; Thrasher, J. Brantley
ISI:000320281602495
ISSN: 0022-5347
CID: 5355572